KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

VEGF pathway inhibitors have been investigated as therapeutic agents in the treatment of non-small cell lung cancer (NSCLC) because of its central role in angiogenesis. These agents have improved survival in patients with advanced NSCLC, but the effects have been modest. Although VEGFR2/KDRis typica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-04, Vol.22 (8), p.1940-1950
Hauptverfasser:	Nilsson, Monique B, Giri, Uma, Gudikote, Jayanthi, Tang, Ximing, Lu, Wei, Tran, Hai, Fan, Youhong, Koo, Andrew, Diao, Lixia, Tong, Pan, Wang, Jing, Herbst, Roy, Johnson, Bruce E, Ryan, Andy, Webster, Alan, Rowe, Philip, Wistuba, Ignacio I, Heymach, John V
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - metabolism Carcinoma, Non-Small-Cell Lung - mortality Cell Line, Tumor Cell Movement - drug effects Cell Proliferation - drug effects Humans Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - mortality p38 Mitogen-Activated Protein Kinases - metabolism Piperidines - pharmacology Piperidines - therapeutic use Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins c-met - metabolism Quinazolines - pharmacology Quinazolines - therapeutic use Signal Transduction - drug effects TOR Serine-Threonine Kinases - metabolism Treatment Outcome Vascular Endothelial Growth Factor A - metabolism Vascular Endothelial Growth Factor Receptor-2 - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!